BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving research platform. New compounds and evidence are added continuously.
B
BiohacksAI/Conditions/Metabolic Syndrome
CONDITION

Evidence-Based Compounds for Metabolic Syndrome

Metabolic syndrome encompasses abdominal obesity, insulin resistance, dyslipidaemia, and hypertension. Compounds with evidence across these interconnected metabolic abnormalities target AMPK activation, PPAR signalling, lipid metabolism, and vascular function — offering multi-target approaches supported by clinical research.

Ranking Methodology
Compounds are ranked using a four-signal weighted model: BiohacksAI discovery score (cross-study convergence across targets), target match (direct overlap with PPARA, PPARG, PRKAA1 and related targets — highest differentiating signal), pathway overlap with INSULIN SIGNALING and AMPK pathways, and PubMed study count (log-scaled). Clinical drugs are excluded.
Key Biological Targets

Click a target to see all compounds with documented interactions in the BiohacksAI corpus.

This page presents computational analysis of published research from PubMed/NCBI, BindingDB, and Reactome. Rankings are based on BiohacksAI discovery score, pathway overlap, and study count. This is not medical advice — consult a healthcare professional before starting any supplement.

Browse all compounds · Biological pathways · Molecular targets · All conditions

© Organiq Sweden AB · Patent pending EVE-PAT-2026-001